Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(b) Resignation of Tim M. Mayleben as President and Chief Executive Officer
On June 18, 2022, Tim M. Mayleben, President and Chief Executive Officer of
Landos Biopharma, Inc. (the "Company"), resigned from those positions, effective
June 20, 2022.
(c)(d)(e) Appointment of Gregory Oakes as Chief Executive Officer and Director
On June 18, 2022, the board of directors of the Company (the "Board") appointed
Gregory Oakes, to serve as the Company's Chief Executive Officer, effective
June 20, 2022. Mr. Oakes will also serve as the Company's principal financial
officer.
Effective June 20, 2022, Mr. Oakes was appointed by the Board to serve as a
Class I director on the Board. Mr. Oakes term will continue until the Company's
2025 annual meeting of stockholders.
Gregory Oakes, age 54 served as President, North America, Vifor Pharma, Inc, and
Executive Vice President, Vifor Pharma from September 2020 until November 2021.
Mr. Oakes served on the board of directors of First Wave BioPharma, Inc. from
April 2020 to June 2022. Mr. Oakes previously served as Corporate Vice
President, Global Integration Lead for Otezla® (apremilast) at Amgen, Inc from
November 2019 to August 2020. Prior to Amgen, Mr. Oakes served as Corporate Vice
President and U.S. General Manager at Celgene Corp from July 2017 to November
2019. Mr. Oakes also served as the Global Commercial Integration Lead at Celgene
where he helped steer the $74 billion acquisition by Bristol-Myers Squibb and
the $13.4 billion divestiture of Otezla®. From January 2010 to July 2017,
Mr. Oakes held several positions at Novartis AG, the most recent as Head of
Sandoz Biopharmaceuticals, North America. He began his career at Schering-Plough
(Merck) where he held executive roles in both the U.S. and Europe. Mr. Oakes
holds a bachelor's degree in Marketing and Business Administration from Edinboro
University and an MBA from Clemson University.
There are no related party transactions between Mr. Oakes and the Company that
would require disclosure under Item 404(a) of Regulation S-K, and there is no
family relationship between Mr. Oakes and any of the Company's directors or
other executive officers.
In connection with his appointment as the Chief Executive Officer of the
Company, Mr. Oakes and the Company entered into an employment agreement,
effective as of June 20, 2022 (the "CEO Employment Agreement").
Under the terms of the CEO Employment Agreement, Mr. Oakes will receive an
initial annual base salary of $600,000 and will be eligible to receive an annual
performance bonus with a target of 60% of Mr. Oakes's base salary. Any actual
annual performance bonus amount will be based upon the Board's good faith
assessment of Mr. Oakes's and the Company's attainment of goals established by
the Board in its reasonable discretion but with input from Mr. Oakes. Mr. Oakes
is also eligible to receive a retention bonus, subject to specific terms and
conditions (the "Retention Bonus"). In accordance with the CEO Employment
Agreement, Mr. Oakes was granted an option to purchase 1,677,251 shares of
common stock with an exercise price equal to the closing price of the Company's
common stock
--------------------------------------------------------------------------------
on June 17, 2022 under the Company's 2019 Equity Incentive Plan (the "Plan").
25% of the shares subject to the option vest on the one year anniversary of the
date of grant and the remaining shares vest in 36 equal monthly installments
thereafter, subject to Mr. Oakes's continued service. Mr. Oakes also entered
into a confidentiality, inventions assignment, non-competition and
non-solicitation agreement with the Company.
Pursuant to the terms of the CEO Employment Agreement, Mr. Oakes's employment is
at will and may be terminated at any time by the Company or Mr. Oakes.
If the Company terminates Mr. Oakes's employment without "Cause," or if
Mr. Oakes terminates his employment for "Good Reason" (each, as defined in the
CEO Employment Agreement) at any time except on or within twelve (12) months
following the effective date of a Corporate Transaction, as defined in the Plan
(the "Corporate Transaction Measurement Period"), Mr. Oakes will be eligible to
receive (i) severance payments, in the form of salary continuation, in an amount
equal to 12 months of his then-current base salary, (ii) payment of COBRA
premiums for a period of up to 12 months, (iii) eligibility of award of a bonus
for the prior calendar year if no bonus has been paid at the time of termination
(the "Completed Year Bonus"); (iv) the pro rata portion of Mr. Oakes's current
year target bonus, prorated to reflect the partial year of service (the "Pro
Rata Bonus"); (iv) forgiveness of his obligation to repay the Retention Bonus,
if applicable; and (v) accelerated vesting of all outstanding unvested
time-based equity awards that would have become vested during the 12 months
following the termination date .
If the Company terminates Mr. Oakes's employment without Cause or if Mr. Oakes
terminates his employment for Good Reason during the Corporate Transaction
Measurement Period, Mr. Oakes will be eligible to receive (i) a lump sum
severance payment in an amount equal to 18 months of his then-current base
salary, (ii) payment of COBRA premiums for a period of up to 18 months,
(iii) eligibility for the Completed Year Bonus; (iv) the Pro Rata Bonus;
(iv) forgiveness of his obligation to repay the Retention Bonus, if applicable;
and (v) 100% accelerated vesting of all outstanding unvested time-based equity
awards as of the termination date.
The severance benefits described above are conditioned upon Mr. Oakes executing
and making effective and irrevocable a separation agreement that includes a
general release as well as his compliance with certain non-competition,
non-solicitation, non-disparagement and non-disclosure obligations, resignation
from all positions with our company and return of all company property.
The foregoing description of the CEO Employment Agreement is not complete and is
qualified in its entirety by reference to the CEO Employment Agreement, which
will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for
the three months ended June 30, 2022.
(e) Bonuses awarded to Tim M. Mayleben and Patricia Bitar
In recognition of services provided to the Company, the Company awarded
Mr. Mayleben a one-time cash bonus of $275,000 as well as an option to purchase
18,000 shares of common stock with an exercise price equal to the closing price
of the Company's common stock on June 17, 2022 under the Plan. The shares
subject to this option will vest in full on June 7, 2023. The Company also
awarded Patricia Bitar, the Company's former Chief Financial Officer, a one-time
cash bonus of $100,000 for services provided to the Company.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses